(Q34795762)

4 August 2017

1 reference

title

Hormone-refractory Prostate Cancer (English)

1 reference

4 August 2017

1 reference

2

Eric J Small

1 reference

4 August 2017

Brian I Rini

1

1 reference

4 August 2017

publication date

1 October 2002

1 reference

Current Treatment Options in Oncology

4 August 2017

published in

1 reference

4 August 2017

volume

3

1 reference

4 August 2017

issue

5

1 reference

4 August 2017

page(s)

437-446

1 reference

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

4 August 2017

cites work

1 reference

12 December 2020

Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade

1 reference

12 December 2020

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome

1 reference

12 December 2020

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

12 December 2020

Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer

1 reference

12 December 2020

A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.

1 reference

12 December 2020

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer

1 reference

12 December 2020

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease

1 reference

12 December 2020

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

1 reference

12 December 2020

Hormone-refractory (D3) prostate cancer: refining the concept.

1 reference

12 December 2020

Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy

1 reference

12 December 2020

Importance of continued testicular suppression in hormone-refractory prostate cancer

1 reference

12 December 2020

Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer

1 reference

12 December 2020

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer

1 reference

12 December 2020

In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3.

1 reference

12 December 2020

Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal

1 reference

12 December 2020

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

12 December 2020

Antiandrogen withdrawal syndrome with nilutamide

1 reference

12 December 2020

Docetaxel (Taxotere) in hormone-refractory prostate cancer.

1 reference

12 December 2020

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

12 December 2020

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

12 December 2020

Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival

1 reference

12 December 2020

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy

1 reference

12 December 2020

Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.

1 reference

12 December 2020

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

12 December 2020

Management of progressive metastatic prostate cancer.

1 reference

12 December 2020

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

1 reference

12 December 2020

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

12 December 2020

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma

1 reference

12 December 2020

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

1 reference

12 December 2020

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

12 December 2020

Phase II study of megestrol acetate for metastatic carcinoma of the prostate

1 reference

12 December 2020

A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate

1 reference

12 December 2020

Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal

1 reference

12 December 2020

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

1 reference

12 December 2020

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

1 reference

12 December 2020

Ketoconazole therapy for hormonally refractive metastatic prostate cancer

1 reference

12 December 2020

Mechanisms of action of taxanes in prostate cancer.

1 reference

12 December 2020

Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

1 reference

12 December 2020

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer

1 reference

12 December 2020

Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group

1 reference

12 December 2020

Nilutamide: possible utility as a second-line hormonal agent

1 reference

12 December 2020

Withdrawal phenomenon with the antiandrogen casodex

1 reference

12 December 2020

10.1007/S11864-002-0008-1

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

1016964643

0 references

Fatcat ID

release_hqzuqe72mfe5tcsqhb5ohyn73u

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hqzuqe72mfe5tcsqhb5ohyn73u

24 November 2022

mapped directly with Wikidata item

1 reference